Sarcoglycans take center stage in gene transfer therapy.
Oliver J
OJ
Müller
Hanns
H
Lochmüller
D000818:Animals; D002986:Clinical Trials as Topic / Q000592:standards; D004195:Disease Models, Animal; D016189:Dystrophin / Q000172:deficiency / Q000235:genetics; D018014:Gene Transfer Techniques / Q000009:adverse effects / Q000639:trends*; D015316:Genetic Therapy / Q000009:adverse effects / Q000379:methods / Q000639:trends*; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D051379:Mice; D008967:Molecular Biology / Q000379:methods / Q000639:trends; D018482:Muscle, Skeletal / Q000378:metabolism / Q000503:physiopathology; D049288:Muscular Dystrophies, Limb-Girdle / Q000235:genetics* / Q000503:physiopathology / Q000628:therapy*; D009220:Myositis / Q000139:chemically induced / Q000235:genetics / Q000276:immunology; D011401:Promoter Regions, Genetic / Q000235:genetics; D018570:Risk Assessment; D049031:Sarcoglycans / Q000172:deficiency* / Q000235:genetics* / Q000633:toxicity
D016189:Dystrophin; D049031:Sarcoglycans